On this page
What belongs in the CTD P.1 drug product description and composition?
Describe each proposed dosage form and presentation, with its components, per-unit quantities, functions and relevant quality standards. Make strengths, quantity bases, overages and any supplied diluent explicit. Reconcile the composition with manufacturing and development records so every section describes the same finished product.
Before you begin
M4Q(R1) P.1 for the proposed finished product, including applicable supplied reconstitution diluents.
What you will prepare: A clear product description and per-unit composition that consistently identifies every proposed presentation.
Build the per-unit description from controlled formulation records
Identify the dosage form and the presentations being proposed. Obtain the approved formulation record and list the components, per-unit quantities, functions and quality-standard references. Show any overage transparently and link its justification in P.2. For multiple strengths, use separate columns or tables so a reader can compare composition without guessing a scaling rule.
Make the quantity basis explicit. Distinguish a drug substance amount from the amount of active moiety it represents, and identify concentrations or fill volumes with units where relevant. Do not force liquid, lyophilized and tablet presentations into an unlabeled “amount” column. A trade name or excipient premix may need composition detail from the responsible supplier or formulation owner.
Describe the presentation the user actually receives
Identify the container and closure type and any accompanying reconstitution diluent. Assess whether separate P information for the diluent is appropriate, as M4Q describes; do not assume it is covered by merely naming it. Cross-reference the detailed component controls in P.7 and compatibility evidence in P.2.6.
Compare the product description with the proposed labeling, P.3 batch formula, P.4 excipient records and development formulation table. Resolve differences through the technical owners rather than selecting the most recent-looking file. If a presentation or strength remains undecided, identify it as unresolved in the working copy and exclude unsupported definitive claims.
Worked review: per-unit and batch quantities disagree
Fictional exercise: P.1 states one amount of an excipient per tablet, but scaling the P.3.2 formula to the declared theoretical batch size produces another. A process loss is offered as an explanation without evidence.
Check units, theoretical yield, any justified overage and the current master formulation with the manufacturing owner. Determine which record represents the proposal and assess the consequences of the difference. Do not hide the mismatch by rounding. Once resolved, review P.2's formulation rationale and the affected strength tables so the application describes one coherent composition.
Build a composition table that can be reconciled
Before drafting P.1, agree the meaning of a unit: a tablet, a defined fill volume, a vial before reconstitution or another appropriate presentation. Do not place all of these beneath an undefined “amount” heading.
| Working column | What the author needs | Check against |
|---|---|---|
| Component and function | Exact identity, grade and intended role | Excipient control and development records |
| Quantity and basis | Per-unit amount, units and any active-moiety relationship | Controlled formulation and assay conventions |
| Strength/presentation | Separate scope where composition differs | Proposed labeling and packaging |
| Overage, if proposed | Declared amount and approved rationale | P.2 discussion and P.3 batch formula |
| Standard | Applicable quality record or reference | Actual material used in the proposal |
This is an editorial table design. The scientific owners supply the actual values and justification. The writer should not infer a formulation by dividing an observed batch yield into the ingredient inputs.
Reconciliation exercise: a vial contains a salt but is labeled by active-moiety amount. Retain both the material identity and the stated strength basis, and ask the formulation and analytical owners to confirm the relationship. Removing the salt name or silently changing the amount would obscure the issue.
For multiple strengths, verify each column rather than assuming proportional scaling. Carry the resolved composition into P.3 manufacturing and P.2 development, including any diluent or reconstitution condition that changes the product description.
Your preparation checklist
0/3 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Should a batch formula be copied directly into P.1?
P.1 describes the product composition on an appropriate per-unit basis, while P.3.2 describes the batch formula. Reconcile them using the defined theoretical batch basis and actual formulation records. Batch inputs, process losses and observed yield are not interchangeable ways to calculate the declared composition.
Can an overage be left out of the composition description?
An overage should be transparent and connected to its justification in pharmaceutical development. The writer must obtain the actual proposal rather than insert a standard percentage or hide it by rounding. Reconcile the per-unit description and batch formula after the technical decision.
Does naming a reconstitution diluent fully document it?
Not necessarily. Identify the supplied diluent and assess the applicable supporting information, including whether a separate product part is appropriate. Connect the product description to the relevant development, compatibility and packaging evidence rather than treating the name alone as complete coverage.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Guidance
ICH M4Q(R1): CTD Quality ↗Step 4, September 12, 2002; Module 3, printed pages 5–18. Organization/content guidance, not a universal list of required studies. Checked September 22, 2026. Guide-specific passages: 3.2.P.1 and diluent footnote, printed page 11.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 3.2.P.1. A heading identifies placement, not mandatory applicability.